Gilbert J. Grant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gilbert J. Grant has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Mylarrao Bansinath
4 shared publicationsBoris Piskoun
3 shared publicationsElijah M. Bolotin
2 shared publicationsHerman Turndorf
2 shared publicationsM. Bansinath
Department of Anesthesiology, New York University School of Medicine, New York, USA
2 shared publicationsYechezkel Barenholz
2 shared publications
Latest Publications
- 1 August 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 106 (2) , 384-387
Simpson, Semmelweis, and Transformational Change
The first anesthetic for childbirth and the first recognition of the importance of hand hygiene in obstetrics coincidentally occurred within 5 months of one another in 1847. More than 150 years later, one would have thought that these milestone events would have been fully integrated into practice. However, individuals resist transformational change, which is defined as a fundamental alteration in their beliefs, attitude, and behavior, even when they are confronted with incontrovertible facts. This resistance to change may explain why, in 2005, a large percentage of health care providers still do not practice acceptable hand hygiene, and the pain of childbirth continues to be extolled by some as a necessary part of womanhood, just as pharmacologic pain relief is discouraged.
- 1 August 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 106 (2) , 384-387
Simpson, Semmelweis, and Transformational Change
The first anesthetic for childbirth and the first recognition of the importance of hand hygiene in obstetrics coincidentally occurred within 5 months of one another in 1847. More than 150 years later, one would have thought that these milestone events would have been fully integrated into practice. However, individuals resist transformational change, which is defined as a fundamental alteration in their beliefs, attitude, and behavior, even when they are confronted with incontrovertible facts. This resistance to change may explain why, in 2005, a large percentage of health care providers still do not practice acceptable hand hygiene, and the pain of childbirth continues to be extolled by some as a necessary part of womanhood, just as pharmacologic pain relief is discouraged.
- 1 July 2004
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 101 (1) , 133-137
A Novel Liposomal Bupivacaine Formulation to Produce Ultralong-Acting Analgesia
Background: Currently available local anesthetics have relatively brief durations of action. An ultralong-acting local anesthetic would benefit patients with acute and chronic pain. The authors prepared and characterized a novel liposomal bupivacaine formulation using remote loading of bupivacaine along an ammonium sulfate gradient and assessed its efficacy in humans. Methods: A large multivesicular liposomal bupivacaine formulation was prepared by subjecting small unilamellar vesicles to successive freeze-and-thaw cycles. Bupivacaine hydrochloride was then remotely loaded into the liposomes along an ammonium sulfate gradient ([(NH4)2SO4)]intraliposome/[(NH4)2SO4)]medium > 1000). The liposomes were then characterized for size distribution; drug-to-phospholipid ratio; in vitro release profile at 4 degree, 21 degree C, and 37 degree C; sterility; and pyrogenicity. Six subjects each received six intradermal injections in the lower back with 0.5 ml of 0.5, 1.0, and 2% liposomal bupivacaine; 0.5% standard bupivacaine; saline; and "empty" liposomes. Duration of analgesia was assessed using pinprick testing of the skin directly over the injection sites. Results were compared using the log-rank test. Results: The mean large multivesicular vesicle size was 2439 +/- 544 nm, with a drug-to-phospholipid ratio of 1.8, fivefold greater than results previously reported. In vitro release was slowest at 4 degree C. The median duration of analgesia with 0.5% standard bupivacaine was 1 h. The median durations of analgesia after 0.5, 1.0, and 2.0% liposomal bupivacaine were 19, 38, and 48 h, respectively. Neither saline nor "empty" liposomes produced analgesia. Conclusions: This novel liposomal formulation had a favorable drug-to-phospholipid ratio and prolonged the duration of bupivacaine analgesia in a dose-dependent manner. If these results in healthy volunteers can be duplicated in the clinical setting, this formulation has the potential to significantly impact the management of pain.
- 1 July 2004
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 101 (1) , 133-137
A Novel Liposomal Bupivacaine Formulation to Produce Ultralong-Acting Analgesia
Background: Currently available local anesthetics have relatively brief durations of action. An ultralong-acting local anesthetic would benefit patients with acute and chronic pain. The authors prepared and characterized a novel liposomal bupivacaine formulation using remote loading of bupivacaine along an ammonium sulfate gradient and assessed its efficacy in humans. Methods: A large multivesicular liposomal bupivacaine formulation was prepared by subjecting small unilamellar vesicles to successive freeze-and-thaw cycles. Bupivacaine hydrochloride was then remotely loaded into the liposomes along an ammonium sulfate gradient ([(NH4)2SO4)]intraliposome/[(NH4)2SO4)]medium > 1000). The liposomes were then characterized for size distribution; drug-to-phospholipid ratio; in vitro release profile at 4 degree, 21 degree C, and 37 degree C; sterility; and pyrogenicity. Six subjects each received six intradermal injections in the lower back with 0.5 ml of 0.5, 1.0, and 2% liposomal bupivacaine; 0.5% standard bupivacaine; saline; and "empty" liposomes. Duration of analgesia was assessed using pinprick testing of the skin directly over the injection sites. Results were compared using the log-rank test. Results: The mean large multivesicular vesicle size was 2439 +/- 544 nm, with a drug-to-phospholipid ratio of 1.8, fivefold greater than results previously reported. In vitro release was slowest at 4 degree C. The median duration of analgesia with 0.5% standard bupivacaine was 1 h. The median durations of analgesia after 0.5, 1.0, and 2.0% liposomal bupivacaine were 19, 38, and 48 h, respectively. Neither saline nor "empty" liposomes produced analgesia. Conclusions: This novel liposomal formulation had a favorable drug-to-phospholipid ratio and prolonged the duration of bupivacaine analgesia in a dose-dependent manner. If these results in healthy volunteers can be duplicated in the clinical setting, this formulation has the potential to significantly impact the management of pain.
- 1 January 2002
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 46 (1) , 90-94
Intrathecal administration of liposomal neostigmine prolongs analgesia in mice
Background: There is substantial evidence that cholinomimetic drugs increase pain threshold. However, the profound side effects of these agents have limited their clinical use either as analgesics or as analgesic adjuncts. A delivery system that would assure a slow and sustained drug release may be of value in ameliorating the problem of untoward effects.Methods: The acetylcholinesterase inhibitor neostigmine was encapsulated into multilamellar lipid vesicles composed of phosphocholine and cholesterol. Three doses of plain or liposomal neostigmine were administered by the intrathecal route to mice (n=8–10/group), and analgesic duration was quantified by tail flick test. The doses were chosen based on preliminary experiments, which showed the maximum tolerated intrathecal doses of plain and liposomal neostigmine formulation were 0.625 μg and 80 μg, respectively. Two other doses for each formulation were then derived by 1:1 serial dilutions. Results were compared using survival analysis.Results: The median antinociceptive duration for plain neostigmine was 0.33, 0.99 and 1.0 h for the 0.115, 0.312 and 0.625 μg doses, respectively. For the liposomal formulation, the median antinociceptive duration was 1.0, 1.5 and 6.0 h for the 20, 40 and 80 μg doses, respectively.Conclusions: Liposomal neostigmine provides prolonged spinal antinociception, and permits the safe administration of a relatively large dose, because drug is gradually released from the liposomal depot. This technology holds promise for the development of a clinically useful neostigmine formulation to provide spinal analgesia.
- 1 January 2002
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 46 (1) , 90-94
Intrathecal administration of liposomal neostigmine prolongs analgesia in mice
Background: There is substantial evidence that cholinomimetic drugs increase pain threshold. However, the profound side effects of these agents have limited their clinical use either as analgesics or as analgesic adjuncts. A delivery system that would assure a slow and sustained drug release may be of value in ameliorating the problem of untoward effects.Methods: The acetylcholinesterase inhibitor neostigmine was encapsulated into multilamellar lipid vesicles composed of phosphocholine and cholesterol. Three doses of plain or liposomal neostigmine were administered by the intrathecal route to mice (n=8–10/group), and analgesic duration was quantified by tail flick test. The doses were chosen based on preliminary experiments, which showed the maximum tolerated intrathecal doses of plain and liposomal neostigmine formulation were 0.625 μg and 80 μg, respectively. Two other doses for each formulation were then derived by 1:1 serial dilutions. Results were compared using survival analysis.Results: The median antinociceptive duration for plain neostigmine was 0.33, 0.99 and 1.0 h for the 0.115, 0.312 and 0.625 μg doses, respectively. For the liposomal formulation, the median antinociceptive duration was 1.0, 1.5 and 6.0 h for the 20, 40 and 80 μg doses, respectively.Conclusions: Liposomal neostigmine provides prolonged spinal antinociception, and permits the safe administration of a relatively large dose, because drug is gradually released from the liposomal depot. This technology holds promise for the development of a clinically useful neostigmine formulation to provide spinal analgesia.
- 1 January 2001
- Published by Springer Nature in Pharmaceutical Research
- Vol. 18 (3) , 336-343
DRV Liposomal Bupivacaine: Preparation, Characterization, and In Vivo Evaluation in Mice
Purpose. To evaluate the dehydration-rehydration technique to prepare a formulation of liposomal bupivacaine, and to assess its analgesic efficacy. Methods. Bupivacaine hydrochloride (BUP) was...
- 1 January 2001
- Published by Springer Nature in Pharmaceutical Research
- Vol. 18 (3) , 336-343
DRV Liposomal Bupivacaine: Preparation, Characterization, and In Vivo Evaluation in Mice
Purpose. To evaluate the dehydration-rehydration technique to prepare a formulation of liposomal bupivacaine, and to assess its analgesic efficacy. Methods. Bupivacaine hydrochloride (BUP) was...
- 1 January 2001
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 26 (1) , 61-63
Liposomal delivery systems for local anesthetics
- 1 January 2001
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 26 (1) , 61-63
Liposomal delivery systems for local anesthetics
- 1 February 2000
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 43 (1) , 69-72
An in vivo method for the quantitative evaluation of local anesthetics
- 1 February 2000
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 43 (1) , 69-72
An in vivo method for the quantitative evaluation of local anesthetics
- 1 February 1998
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 86 (2S) , 427S
INTRAVENOUS ANESTHETICS INHIBIT CEREBELLAR GUANYLATE CYCLASE ENZYME
- 1 February 1998
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 86 (2S) , 427S
INTRAVENOUS ANESTHETICS INHIBIT CEREBELLAR GUANYLATE CYCLASE ENZYME